Douglas R. Hough

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Richard Furie, Michelle Petri, Omid Zamani et al. · Arthritis & Rheumatism · 2011 · 1.7K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

Arthur Kavanaugh, Philip J. Mease, Juan J. Gómez‐Reino et al. · Annals of the Rheumatic Diseases · 2014 · 441 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

William Stohl, Falk Hiepe, Kevin Latinis et al. · Arthritis & Rheumatism · 2012 · 416 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

Susan Manzi, Jorge Sánchez‐Guerrero, Joan T. Merrill et al. · Annals of the Rheumatic Diseases · 2012 · 407 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

Effect of Belimumab on Vaccine Antigen Antibodies to Influenza, Pneumococcal, and Tetanus Vaccines in Patients with Systemic Lupus Erythematosus in the BLISS-76 Trial

Winn Chatham, Daniel J. Wallace, William Stohl et al. · The Journal of Rheumatology · 2012 · 95 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17